Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy

Table 2 Univariate and multivariate analysis of overall survival for Siewert type II adenocarcinoma of the esophagogastric junction underwent radical gastrectomy with neoadjuvant chemotherapy

	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age
< 65 yr	1
≥ 65 yr	1.11	0.93-1.33	0.259
Sex
Male	1			1
Female	0.81	0.62-1.06	0.120	0.74	0.57-0.98	0.035
Marital status
Married	1			1
Divorced or separated	1.38	1.05-1.8	0.019	1.51	1.15-1.99	0.003
Single (never married)	1.11	0.85-1.46	0.435	1.07	0.81-1.4	0.642
Widowed	1.40	0.91-2.15	0.130	1.34	0.86-2.08	0.198
Others	0.77	0.43-1.37	0.368	0.74	0.41-1.31	0.302
Race
White	1			1
Others	0.81	0.6-1.1	0.173	0.8	0.59-1.08	0.148
Year of diagnosis
2004-2009	1
2010-2015	1.01	0.84-1.22	0.910
Type of surgery
Subtotal gastrectomy	1
Total gastrectomy	1.04	0.83-1.3	0.762
Tumor size
< 50 mm	1
≥ 50 mm	1.08	0.88-1.32	0.477
The number of examined lymph nodes	1	0.99-1	0.379
yp T stage
T1	1			1
T2	1.42	0.96-2.1	0.082	1.25	0.84-1.87	0.265
T3	1.89	1.36-2.63	< 0.001	1.43	1.01-2.02	0.043
T4a	2.66	1.82-3.88	< 0.001	1.85	1.24-2.75	0.003
yp N stage
N0	1			1
N1	1.40	1.1-1.78	0.006	1.37	1.07-1.76	0.012
N2	1.90	1.49-2.42	< 0.001	1.84	1.42-2.38	< 0.001
N3	3.13	2.37-4.12	< 0.001	3.11	2.31-4.18	< 0.001
Grade
Well differentiated	1
Moderate differentiated	0.87	0.56-1.35	0.539
Low differentiated	1.31	0.86-2	0.211
Gx	1.01	0.58-1.77	0.976
Adjuvant chemotherapy
No	1			1
Yes	0.80	0.63-1.02	0.067	0.67	0.52-0.85	0.001

HR: Hazard ratio.